ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Karyopharm Therapeutics, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 8.04% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -4.72
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 103.15%, its profits have fallen by -10.5%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Karyopharm Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Karyopharm Therapeutics, Inc.
103.15%
-0.39
97.42%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
6.21%
EBIT Growth (5y)
8.04%
EBIT to Interest (avg)
-4.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.54
Sales to Capital Employed (avg)
10.63
Tax Ratio
0.04%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
65.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.34
EV to EBIT
-2.92
EV to EBITDA
-2.93
EV to Capital Employed
-2.05
EV to Sales
1.81
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -59.12 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 5.16 times
RAW MATERIAL COST(Y)
Fallen by -0.76% (YoY
PRE-TAX PROFIT(Q)
Highest at USD -22.39 MM
NET PROFIT(Q)
Highest at USD -22.39 MM
EPS(Q)
Highest at USD -1.24
-1What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 154.59 MM
Here's what is working for Karyopharm Therapeutics, Inc.
Debtors Turnover Ratio
Highest at 5.16 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Operating Cash Flow
Highest at USD -59.12 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
Highest at USD -22.39 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -22.39 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -1.24
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -0.76% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Karyopharm Therapeutics, Inc.
Cash and Eqv
Lowest at USD 154.59 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
